Table 3. Associations between IDO activity and changes with progression-free survival and overall survival of NSCLC.
| Timepoints | IDO activities | Patients (n) | PFS | OS | |||||
|---|---|---|---|---|---|---|---|---|---|
| Progression n (%) | mPFS (months) | P value | Death n (%) | mOS (months) | P value | ||||
| Pre-RT (n=104) | Kynurenine | 0.200 | 0.287 | ||||||
| ≤ Median | 52 | 25 (48.1) | 26.8 | 18 (34.6) | 30.3 | ||||
| > Median | 52 | 37 (71.2) | 14.3 | 26 (50.0) | 33.7 | ||||
| Kyn:Trp ratio | 0.049 | 0.131 | |||||||
| ≤ Median | 52 | 25 (48.1) | 24.5 | 17 (32.7) | Not reached | ||||
| > Median | 52 | 37 (71.2) | 13.5 | 27 (51.9) | 26.8 | ||||
| Post-RT (n=84) | Kynurenine | 0.500 | 0.598 | ||||||
| ≤ Median | 42 | 21 (50.0) | 18.9 | 16 (38.1) | Not reached | ||||
| > Median | 42 | 29 (69.0) | 19.5 | 22 (52.4) | 30.2 | ||||
| Kyn:Trp ratio | 0.693 | 0.401 | |||||||
| ≤ Median | 42 | 24 (57.1) | 16.1 | 20 (47.6) | 23.7 | ||||
| > Median | 42 | 26 (61.9) | 19.5 | 18 (42.9) | Not reached | ||||
| Post/Pre (n=84) | Kynurenine | 0.879 | 0.414 | ||||||
| ≤ Median | 42 | 25 (59.5) | 16.1 | 21 (50.0) | 30.2 | ||||
| > Median | 42 | 25 (59.5) | 19.9 | 17 (40.5) | Not reached | ||||
| Kyn:Trp ratio | 0.084 | 0.032 | |||||||
| ≤ Median | 42 | 28 (66.7) | 12.3 | 24 (57.1) | 23.8 | ||||
| > Median | 42 | 22 (52.4) | 29.1 | 14 (33.3) | Not reached | ||||
IDO, indoleamine 2,3-dioxygenase; NSCLC, non-small cell lung cancer; PFS, progression-free survival; OS, overall survival; mPFS, median progression-free survival; mOS, median overall survival; Kyn, kynurenine; Trp, tryptophan; RT, radiotherapy.